This study is being conducted to determine the effectiveness of a lower monotherapy dose of
lamotrigine than that currently approved.
Inclusion criteria:
- Male or Female ≥13 years of age
- Have a confident diagnosis of epilepsy with partial seizures for at least 24 weeks
prior to the Baseline Phase
- Have a documented history of partial seizures such that the investigator must judge
that the subject is likely to have at least 4 partial seizures during the 8-week
Baseline Phase.
- Have experienced at least 4 partial seizures (i. e., simple or complex partial seizures
with or without secondary generalization) during an 8-week (i. e., 56 days) prospective
Baseline Phase with at least one partial seizure occurring during each 4-week (i. e.,
28-day) period.
- NOTE: With prior authorization from GlaxoSmithKline (GSK), retrospective data may
take the place of up to the first 4 weeks (i. e., first 28 days) of the Baseline Phase
for subjects providing reliable documentation of the following (see Appendix 3):
1. A complete daily seizure diary that includes the number, and type (i. e., simple
or complex partial seizures with or without secondary generalization), of
seizures experienced each day for up to 28 consecutive days immediately prior to
the prospective Baseline Phase
2. Stability of prescribed dosages of background AED
3. Compliance with background AED
All subjects permitted to use retrospective baseline data must complete a minimum of four
weeks (i. e., 28 days) of the prospective Baseline Phase. The retrospective plus the
prospective Baseline Phases must equal the 56 consecutive days prior to the start of dosing
with study drug.
- be currently receiving AED monotherapy treatment with a stable regimen of a non-enzyme
inducing AED for at least four weeks prior to starting the Baseline Phase.
- be able and willing to maintain an accurate, complete, written daily seizure diary, or
has a parent/caregiver who is able and willing to maintain and accurate, complete,
written daily seizure diary for the entire duration of the study.
- be able to comply with the dosing of study drugs, background AED, and all study
procedures.
- understand and sign written informed consent, or will have a parent or a legally
authorized representative who has done so, prior to the performance of any study
assessments
- if female, and of childbearing potential be using an acceptable form of birth control,
to include one of the following:
1. Complete abstinence from intercourse for two weeks before exposure to the study
drug, throughout the clinical trial, and for a period after the trial to account
for elimination of the drug (a minimum of 2 weeks).
2. Consistent and correct use of one of the following methods of birth control:
Male partner who is sterile prior to the female subject's entry into the study and is the
sole sexual partner for that female subject.
Any intrauterine device (IUD) with a documented failure rate of less than 1% per year
Double barrier method consisting of spermicide plus a mechanical barrier (e. g., spermicide
plus a male condom or a female diaphragm).
NOTE: Women who have had a hysterectomy, tubal ligation, or are post-menopausal are
considered to be of non-childbearing potential.
NOTE: A pharmacokinetic interaction has been observed between LTG and estrogen-based oral
contraceptives. Therefore, the use of hormonal therapy (e. g., for contraception or hormone
replacement therapy) is not allowed.
Exclusion criteria:
- Exhibits any primary generalized seizures (e. g., absence, myoclonic primary
generalized tonic-clonic seizures).
- Has had status epilepticus within the 24 weeks prior to, or during, the Baseline
Phase.
- Is taking an enzyme-inducing AED (EIAED - e. g. carbamazepine, phenytoin,
phenobarbital, primidone) or is taking more than 1 background AED.
- Is currently taking LTG or has previously had an adequate trial of LTG.
- Is currently taking felbamate
- Is using hormone therapy
- Is abusing alcohol and/or other substances
- Has taken an investigational drug within the previous 30 days or plans to take an
investigational drug anytime during the study.
- Is receiving chronic treatment with any medication that could influence seizure
control
- NOTE: Use of benzodiazepines is allowed as specified in Section 8. 1.2
- Is currently following the ketogenic diet.
- Is using vagal nerve stimulation
- Is planning surgery to control seizures during the study.
- Is pregnant, breastfeeding, or planning to become pregnant during the study or within
the three weeks after the last dose of study drug.
- Is suffering from acute or progressive neurological disease, severe psychiatric
disease or severe mental abnormality that is likely to interfere with the objectives
of the study.
- Has any clinically significant cardiac, renal, hepatic condition, or a condition that
affects the absorption, distribution, metabolism or excretion of drugs.
GSK Clinical Trials Call Center, Buenos Aires 1181, Argentina
GSK Clinical Trials Call Center, Ciudad Autonoma de Buenos Aires 1425, Argentina
GSK Clinical Trials Call Center, Buenos Aires, Argentina
GSK Clinical Trials Call Center, Santiago, Chile
GSK Clinical Trials Call Center, San Jose, Costa Rica
GSK Clinical Trials Call Center, Daejeon 301-721, Korea, Republic of
GSK Clinical Trials Call Center, Seoul 120-752, Korea, Republic of
GSK Clinical Trials Call Center, Pusan 614-735, Korea, Republic of
GSK Clinical Trials Call Center, Daegu 700-712, Korea, Republic of
GSK Clinical Trials Call Center, Seoul 135-170, Korea, Republic of
GSK Clinical Trials Call Center, Seoul 110-744, Korea, Republic of
GSK Clinical Trials Call Center, San Juan 00936, Puerto Rico
GSK Clinical Trials Call Center, San Juan 00918, Puerto Rico
GSK Clinical Trials Call Centre, St. Petersburg 193019, Russian Federation
GSK Clinical Trials Call Centre, Moscow 117049, Russian Federation
GSK Clinical Trials Call Centre, Moscow 105066, Russian Federation
GSK Clinical Trials Call Centre, Moscow 111539, Russian Federation
GSK Clinical Trials Call Centre, Moscow 125412, Russian Federation
GSK Clinical Trials Call Centre, St. Petersburg 193167, Russian Federation
GSK Clinical Trials Call Centre, Ekaterinburg 620102, Russian Federation
GSK Clinical Trials Call Centre, St. Petersburg 194291, Russian Federation
GSK Clinical Trials Call Centre, Samara 443095, Russian Federation
GSK Clinical Trials Call Centre, Kyiv 04050, Ukraine
GSK Clinical Trials Call Centre, Dnepropetrovsk 49616, Ukraine
GSK Clinical Trials Call Centre, Odesa 65006, Ukraine
GSK Clinical Trials Call Centre, Kyiv 02660, Ukraine
GSK Clinical Trials Call Centre, Kharkiv 61068, Ukraine
GSK Clinical Trials Call Centre, Zaporizhzhya 69057, Ukraine
GSK Clinical Trials Call Centre, Lviv 79000, Ukraine
GSK Clinical Trials Call Centre, Vinnitsa 21018, Ukraine
GSK Clinical Trials Call Centre, Lugansk 91045, Ukraine
GSK Clinical Trials Call Centre, Donetsk 83037, Ukraine
GSK Clinical Trials Call Centre, Poltava 36006, Ukraine
GSK Clinical Trials Call Center, Alabaster, Alabama 35007, United States
GSK Clinical Trials Call Center, Birmingham, Alabama 35294, United States
GSK Clinical Trials Call Center, Mesa, Arizona 85201, United States
GSK Clinical Trials Call Center, Phoenix, Arizona 85013, United States
GSK Clinical Trials Call Center, Tucson, Arizona 857224, United States
GSK Clinical Trials Call Center, Sun City, Arizona 85351, United States
GSK Clinical Trials Call Center, Tucson, Arizona 85741, United States
GSK Clinical Trials Call Center, Phoenix, Arizona 05003, United States
GSK Clinical Trials Call Center, Fayetteville, Arkansas 72703, United States
GSK Clinical Trials Call Center, Santa Monica, California 90404, United States
GSK Clinical Trials Call Center, Santa Ana, California 92705, United States
GSK Clinical Trials Call Center, Pasadena, California 91105, United States
GSK Clinical Trials Call Center, Los Angeles, California 90073, United States
GSK Clinical Trials Call Center, Danbury, Connecticut 06810, United States
GSK Clinical Trials Call Center, Fairfield, Connecticut 06824, United States
GSK Clinical Trials Call Center, Washington, District of Columbia 20007, United States
GSK Clinical Trials Call Center, Loxahatchee, Florida 33470, United States
GSK Clinical Trials Call Center, Jacksonville, Florida 32224, United States
GSK Clinical Trials Call Center, Sunrise, Florida 33351, United States
GSK Clinical Trials Call Center, Tampa, Florida 33613, United States
GSK Clinical Trials Call Center, Atlanta, Georgia 30342, United States
GSK Clinical Trials Call Center, Suwanee, Georgia 30024, United States
GSK Clinical Trials Call Center, Decatur, Georgia 30033, United States
GSK Clinical Trials Call Center, Boise, Idaho 90073, United States
GSK Clinical Trials Call Center, Chicago, Illinois 60611, United States
GSK Clinical Trials Call Center, Chicago, Illinois 60637, United States
GSK Clinical Trials Call Center, Flossmoor, Illinois 60422, United States
GSK Clinical Trials Call Center, Urbana, Illinois 61801, United States
GSK Clinical Trials Call Center, Des Moines, Iowa 50309, United States
GSK Clinical Trials Call Center, Lexington, Kentucky 40536, United States
GSK Clinical Trials Call Center, Lexington, Kentucky 40503, United States
GSK Clinical Trials Call Center, Louisville, Kentucky 40202, United States
GSK Clinical Trials Call Center, Baton Rouge, Louisiana 70808, United States
GSK Clinical Trials Call Center, Glen Burnie, Maryland 21061, United States
GSK Clinical Trials Call Center, Pikesville, Maryland 21208, United States
GSK Clinical Trials Call Center, Baltimore, Maryland 21215, United States
GSK Clinical Trials Call Center, Boston, Massachusetts 02215, United States
GSK Clinical Trials Call Center, Springfield, Massachusetts 01104, United States
GSK Clinical Trials Call Center, Detroit, Michigan 48202, United States
GSK Clinical Trials Call Center, St. Cloud, Minnesota 56303, United States
GSK Clinical Trials Call Center, Minneapolis, Minnesota 55455, United States
GSK Clinical Trials Call Center, Hattiesburg, Mississippi 39401, United States
GSK Clinical Trials Call Center, St. Louis, Missouri 63110, United States
GSK Clinical Trials Call Center, St. Louis, Missouri 63110, United States
GSK Clinical Trials Call Center, Las Vegas, Nevada 89103, United States
GSK Clinical Trials Call Center, Henderson, Nevada 89104, United States
GSK Clinical Trials Call Center, Henderson, Nevada 89052, United States
GSK Clinical Trials Call Center, Newark, New Jersey 07103, United States
GSK Clinical Trials Call Center, Cherry Hill, New Jersey 08034, United States
GSK Clinical Trials Call Center, Edison, New Jersey 08818, United States
GSK Clinical Trials Call Center, Newark, New Jersey 19713, United States
GSK Clinical Trials Call Center, Plainview, New York 11803, United States
GSK Clinical Trials Call Center, Syracuse, New York 13210, United States
GSK Clinical Trials Call Center, Lawrence, New York 11559, United States
GSK Clinical Trials Call Center, Asheville, North Carolina 28806, United States
GSK Clinical Trials Call Center, Columbus, Ohio 43210, United States
GSK Clinical Trials Call Center, Oklahoma City, Oklahoma 73112, United States
GSK Clinical Trials Call Center, Sellersville, Pennsylvania 18960, United States
GSK Clinical Trials Call Center, Philadelphia, Pennsylvania 19107, United States
GSK Clinical Trials Call Center, San Antonio, Texas 78229, United States
GSK Clinical Trials Call Center, Dallas, Texas 75230, United States
GSK Clinical Trials Call Center, Houston, Texas 77025, United States
GSK Clinical Trials Call Center, San Antonio, Texas 78258, United States
GSK Clinical Trials Call Center, San Antonio, Texas 78229, United States
GSK Clinical Trials Call Center, Temple, Texas 76502, United States
GSK Clinical Trials Call Center, Midvale, Utah 84047, United States
GSK Clinical Trials Call Center, Renton, Washington 98055, United States
GSK Clinical Trials Call Center, Morgantown, West Virginia 26506, United States
GSK Clinical Trials Call Center, Charleston, West Virginia 25301, United States
GSK Clinical Trials Call Center, Madison, Wisconsin 53715, United States
GSK Clinical Trials Call Center, Milwaukee, Wisconsin 53215, United States
